WO2014163518A1 - Treatments involving eslicarbazepine or eslicarbazepine acetate - Google Patents
Treatments involving eslicarbazepine or eslicarbazepine acetate Download PDFInfo
- Publication number
- WO2014163518A1 WO2014163518A1 PCT/PT2014/000021 PT2014000021W WO2014163518A1 WO 2014163518 A1 WO2014163518 A1 WO 2014163518A1 PT 2014000021 W PT2014000021 W PT 2014000021W WO 2014163518 A1 WO2014163518 A1 WO 2014163518A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- bipolar disorder
- use according
- patient
- esl
- Prior art date
Links
- QIALRBLEEWJACW-INIZCTEOSA-N eslicarbazepine acetate Chemical compound CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12 QIALRBLEEWJACW-INIZCTEOSA-N 0.000 title claims abstract description 134
- 229960003233 eslicarbazepine acetate Drugs 0.000 title claims abstract description 130
- BMPDWHIDQYTSHX-AWEZNQCLSA-N (S)-MHD Chemical compound C1[C@H](O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 BMPDWHIDQYTSHX-AWEZNQCLSA-N 0.000 title claims abstract description 25
- 229960004028 eslicarbazepine Drugs 0.000 title claims abstract description 25
- 238000011282 treatment Methods 0.000 title claims description 94
- 208000020925 Bipolar disease Diseases 0.000 claims abstract description 140
- 239000003814 drug Substances 0.000 claims abstract description 104
- 229940079593 drug Drugs 0.000 claims abstract description 89
- 206010026749 Mania Diseases 0.000 claims description 63
- 230000002265 prevention Effects 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 230000004044 response Effects 0.000 claims description 18
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 208000020401 Depressive disease Diseases 0.000 claims description 10
- 230000001505 hypomanic effect Effects 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 238000009097 single-agent therapy Methods 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 4
- 238000009115 maintenance therapy Methods 0.000 claims description 2
- 229940068196 placebo Drugs 0.000 description 33
- 239000000902 placebo Substances 0.000 description 33
- 230000036651 mood Effects 0.000 description 25
- 208000024891 symptom Diseases 0.000 description 19
- 230000008859 change Effects 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 13
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 229960000623 carbamazepine Drugs 0.000 description 10
- 230000001154 acute effect Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000003001 depressive effect Effects 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 238000011084 recovery Methods 0.000 description 7
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 6
- 229910052744 lithium Inorganic materials 0.000 description 6
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 6
- 208000028017 Psychotic disease Diseases 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 5
- 229960001848 lamotrigine Drugs 0.000 description 5
- 229960004431 quetiapine Drugs 0.000 description 5
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 229940102566 valproate Drugs 0.000 description 5
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 239000000164 antipsychotic agent Substances 0.000 description 4
- 229940005529 antipsychotics Drugs 0.000 description 4
- 229960004372 aripiprazole Drugs 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 229960005017 olanzapine Drugs 0.000 description 4
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 4
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 4
- 229960001816 oxcarbazepine Drugs 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229960001534 risperidone Drugs 0.000 description 4
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- -1 troches Substances 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 206010066901 Treatment failure Diseases 0.000 description 3
- 229940049706 benzodiazepine Drugs 0.000 description 3
- 150000001557 benzodiazepines Chemical class 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 3
- 235000013681 dietary sucrose Nutrition 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229940126601 medicinal product Drugs 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007788 roughening Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- BMPDWHIDQYTSHX-CQSZACIVSA-N (R)-MHD Chemical compound C1[C@@H](O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 BMPDWHIDQYTSHX-CQSZACIVSA-N 0.000 description 2
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 description 2
- LCGTWRLJTMHIQZ-UHFFFAOYSA-N 5H-dibenzo[b,f]azepine Chemical compound C1=CC2=CC=CC=C2NC2=CC=CC=C21 LCGTWRLJTMHIQZ-UHFFFAOYSA-N 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 206010054089 Depressive symptom Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 208000033618 Elevated mood Diseases 0.000 description 2
- 206010015535 Euphoric mood Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000032140 Sleepiness Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000003561 anti-manic effect Effects 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229960001508 levocetirizine Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000011418 maintenance treatment Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 201000009032 substance abuse Diseases 0.000 description 2
- 231100000736 substance abuse Toxicity 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010066364 Hypersexuality Diseases 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030194 Oesophageal stenosis Diseases 0.000 description 1
- 206010057372 Paraesthesia oral Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000007888 Sinus Tachycardia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000003179 convulsant agent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000001544 dysphoric effect Effects 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000002743 euphoric effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- BMPDWHIDQYTSHX-UHFFFAOYSA-N licarbazepine Chemical compound C1C(O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 BMPDWHIDQYTSHX-UHFFFAOYSA-N 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 238000009136 lithium therapy Methods 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 208000022610 schizoaffective disease Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940084026 sodium valproate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 239000000664 voltage gated sodium channel blocking agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Definitions
- the invention relates to new therapeutic techniques involving eslicarbazepine acetate or eslicarbazepine.
- Bipolar disorder is a chronic, recurrent, severe, and often debilitating illness characterised by one or more episodes of mania, depression and long-term
- Bipolar disorders in general include bipolar disorder and unstable bipolar disorder with rapid fluctuations (rapid cyclers), manic-depressive disorders, acute mania, mood episodes, and manic and hypomanic episodes.
- Bipolar Disorder 1 is characterized by one or more manic or mixed mood episodes, usually accompanied by Major Depressive Episodes. Subsequent episodes (that can be either manic or depressive) are common. The estimated prevalence of Bipolar Disorder 1 ranges from 0.4—1.6%; different figures are mostly due to differences in the populations analysed and the definitions employed.
- a manic episode is a period of abnormally elevated mood, accompanied by abnormal behavior that disrupts life, and includes, for example, flying suddenly from one idea to the next; rapid, "pressured,” and loud speech; increased energy, with hyperactivity and a decreased need for sleep; inflated self-image; excessive spending; hypersexuality; and/or substance abuse. Elevated mood can manifest itself as either euphoria or as irritability.
- Bipolar Disorder 1 Many people with Bipolar Disorder 1 also suffer from episodes of depression. There may be a cycling between episodes of mania and depression. In between episodes of mania and depression, many people suffering from Bipolar Disorder 1 experience periods of remission or recovery whic are essentially symptom free, and can live normal lives. There is therefore a genuine clinical benefit in a safe and effective therapy which can prevent the recurrence or relapse of Bipolar Disorder 1 in patients manifesting as episodes, for example manic, hypomanic, depressive or mixed episodes.
- a minority of sufferers have rapid-cycling periods of manic and depressive episodes, with distinct periods of mania or depression four or more times within a year.
- a mixed episode is characterized by the simultaneous occurrence of manic and depressive symptoms, or the fluctuation between manic and depressive symptoms within the same day.
- Management of bipolar disorder patients includes both the treatment of acute manic/depressive episodes and the prevention of recurrent mood episodes.
- Lithium, valproate or atypical antipsychotics are usually first line treatment for acute mania episodes whereas haloperidol and carbamazepine are used as second line alternatives.
- Manic episodes usually begin abruptly and last for between 2 weeks and 4-5 months (median duration about 4 months). Depressive episodes tend to last longer (median duration about 6 months). Recovery may or may not be complete between episodes.
- the pattern of remissions/recovery and relapses/recurrences is very variable, although remissions tend to get shorter as time goes on and depressions to become commoner and longer lasting.
- a return of symptoms at a subsyndi mal level (sometimes referred to as "roughening") may give an indication of a relapse/recurrence. Whilst acute
- Maintenance treatment is the use of a drug over a prolonged period of time. Such maintenance treatment can be used, for example, to reduce the severity of each acute episode as and when it arises, or to reduce the frequency of an episode associated with Bipolar Disorder 1.
- AE adverse events
- Eslicarbazepine acetate ((S)-l 0-acetoxy-l 0, 11 -dihydro-5H-dibenz[b,fJazepine-5- carboxamide) is a potent voltage-gated sodium channel blocker described, e.g., in WO- A-97/02250, WO-A-2006/121363, WO-A-2007/094694, WO-A-2008/088233, WO-A- 2009/054743, WO-A-201 1/014084, WO-A-2011/031176, and WO-A- 2012/091593, the contents of which applications are incorporated herein by reference.
- Eslicarbazepine acetate has been approved by the European Medicines Agency (EMA) for adjunctive therapy for partial-onset seizures, with or without secondary
- Eslicarbazepine acetate is one of several drugs in the carboxamide dibenzazepine family. Other drugs in this family include oxcarbazepine ( 10, 11 -dihydro- 10-oxo-5H- dibenz[b,fJazepine-5-carboxamide, OXC) and carbamazepine (5H- dibenzo[b,fJazepine-5-carboxamide, CBZ). Eslicarbazepine acetate gives reduced production of toxic metabolites compared to carbamazepine, leading to a better tolerability profile.
- Eslicarbazepine acetate is metabolized in vivo in humans to the active metabolite, eslicarbazepine ((5)-10-hydroxy-10,l l-dihydro-5H-dibenz[b,fJazepine-5- carboxamide), with R-licarbazepine and OXC as minor metabolites. Details can be found in "The Treatment of Epilepsy", 3 rd edition, eds. Shorvon, Perucca & Engel, Chapter 38 (Almeida, L et al) (2009), the contents of which are incorporated herein by reference. Oxcarbazepine is also known to be metabolized in vivo in humans to eslicarbazepine and R-licarbazepine in a ratio of approximately 4: 1.
- the present invention provides a drug selected from eslicarbazepine acetate and eslicarbazepine, for use in preventing the recurrence/relapse of Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 in a human patient.
- the present invention also provides a pharmaceutical composition for use in preventing the recurrence/relapse of Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 as defined herein, in a patient as defined herein, which pharmaceutical composition comprises a pharmaceutically acceptable carrier and, as active principle, a drug as defined herein.
- the present invention also provides use of a drug as defined herein, or a
- compositions as defined herein in the manufacture of a medicament for use in preventing recurrence/relapse of Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 as defined herein, in a patient as defined herein.
- the present invention also provides a method of preventing the recurrence/relapse of Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 as defined herein, in a patient as defined herein, which method comprises administering to said patient a safe and effective amount of a drug as defined herein, or a
- the present invention also provides a method of preventing the recurrence/relapse of Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 as defined herein, which method comprises: (a) selecting a patient as defined herein; and
- Figure 1 shows patient disposition for the clinical trials described in the Examples section.
- Figure 2 shows the relative change from baseline in total Young Mania Rating Scale score in study BIA-2093-203.
- Figure 3 shows the proportion of patients in full remission over the 3-week treatment period of study BIA-2093-203.
- Figure 4 shows the Highest and Lowest mood scores (patient diary card) in open-label and double-blind period (by weeks) of study BIA-2093-205 using a visual analogue scale.
- treatment and “treating” are to be understood as embracing treatment and/or amelioration and/or prevention of or reduction in
- preventing is art- recognized, and when used in relation to a condition, such as Bipolar Disorder 1 and its associated episodes, is well understood in the art, and includes administration of a drug and/or composition which reduces the frequency of, or delays the onset of, symptoms of a medical condition in a subject relative to a subject which does not receive the drug or composition.
- a drug chosen from eslicarbazepine acetate and
- eslicarbazepine is used to prevent the recurrence/relapse of Bipolar Disorder 1 and or one or more episodes associated with Bipolar Disorder 1.
- Bipolar Disorder 1 manifests as mood episodes, so the drug chosen from
- eslicarbazepine acetate and eslicarbazepine is typically used to prevent the
- Typical episodes include manic with or without psychotic symptoms, hypomanic, cyclothymic, euthymic, psychotic, euphoric, dysphoric, mixed and/or depressive with or without psychotic symptoms episodes.
- Depressive episodes can be mild, moderate or severe.
- eslicarbazepine is used to prevent the recurrence/relapse of one or more manic, hypomanic, mixed and/or depressive episodes associated with Bipolar Disorder 1.
- prevention of the recurrence or relapse of Bipolar Disorder 1 includes, for example, delaying the onset (prolonging the time between episodes) or reducing the number (incidence), frequency, severity or duration of one or more of the typical episodes defined above in a treated population versus a control population untreated with eslicarbazepine or eslicarbazepine acetate, e.g., by a statistically and/or clinically significant amount. It is of clinical benefit to prevent recurrence/relapse of Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder for as long a period of time as possible to ensure the best quality of life for the patient.
- Remission may be defined as absence or minimal symptoms of one or more episodes for at least one week, typically without worsening of symptoms of the opposite pole, for example reduced symptoms of depression does not involve worsening of manic symptoms.
- prevention of recurrence/relapse refers to prevention of recurrence for a particular period of time, typically a period of at least one week, or one month or more, two months or more, or three months or more, or 6 months or more, or 9 months or more, or 12 months or more, or 15 months or more, or 18 months or more, or 21 months or more, or 24 months or more.
- Prevention over a longer period of time may referred to as “recovery” or "sustained remission”.
- Reference to "recurrence” or “relapse” indicates that a patient has previously suffered from Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1, as defined above.
- the patient has previously experienced one or more manic, hypomanic, mixed and/or depressive episodes, or one or more manic, hypomanic and/or mixed episodes, or one or more manic and/or mixed episodes, or one or more manic episodes.
- the patient has been diagnosed as suffering from Bipolar Disorder 1 in accordance with DSM-IV, the entirety of which is incorporated herein by reference.
- the patient has previously experienced one or more episodes associated with Bipolar Disorder 1 as defined herein and the drug for use in the present invention acts to prevent further such episodes of any duration.
- a return of symptoms at a subsyndromal level (sometimes referred to as “roughening") may precede a relapse/recurrence, and trigger the need for administration of a drug according to the invention.
- a patient has experienced one or more episodes associated with Bipolar Disorder 1, as defined above, and essentially symptom free periods ("remission” or “recovery”) between episodes.
- eslicarbazepine and eslicarbazepine acetate typically extends those symptom free periods for as long as possible, for example for a particular period of time, as defined above.
- the patient suffers from rapid-cycling Bipolar Disorder 1.
- a typical clinical situation presented in the treatment of Bipolar Disorder 1 is a patient suffering from an acute episode, typically a manic, hypomanic or mixed episode, usually a manic or mixed episode.
- the task of the clinician is first to address the acute episode, and also to set up a regime to prevent recurrence/relapse of Bipolar Disorder 1 and/or the episodes associated therewith for as long a time as is possible.
- a patient treated in accordance with the present invention has previously been treated for Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1.
- the patient has previously been treated for Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1
- the patient treated in accordance with the present invention is typically no longer suffering from Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1, i.e. the patient is in remission or recovery.
- this previous treatment involves administering one or more therapeutic agents which are effective in treating Bipolar Disorder 1 and/or episodes associated with Bipolar Disorder as defined above.
- This previous treatment may also involve convulsant therapy, such as electroconvulsant therapy.
- the patient has previously been treated for Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 using one or more therapeutic agents for the treatment of Bipolar Disorder 1 and/or episodes associated with Bipolar Disorder 1, as defined above.
- the one or more therapeutic agents include
- the one or more therapeutic agents are other than eslicarbazepine acetate and/or eslicarbazepine and may, for instance, include lithium, anticonvulsants such as (sodium) valproate, carbamazepine, and lamotrigine, and antipsychotics such as risperidone, olanzapine and aripiprazole.
- anticonvulsants such as (sodium) valproate, carbamazepine, and lamotrigine
- antipsychotics such as risperidone, olanzapine and aripiprazole.
- the patient is unresponsive to or does not tolerate treatment with another therapeutic agent such as lithium, (sodium) valproate, carbamazepine, lamotrigine, risperidone, olanzapine and/or aripiprazole.
- another therapeutic agent such as lithium, (sodium) valproate, carbamazepine, lamotrigine, risperidone, olanzapine and/or aripiprazole.
- treatment with another therapeutic agent such as lithium, (sodium) valproate, carbamazepine, lamotrigine, risperidone, olanzapine and/or aripiprazole is contra- indicated.
- the patient has previously been treated for Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 using eslicarbazepine acetate and/or esUcarbazepine, and eslicarbazepine acetate and/or eslicarbazepine is then also used to prevent recurrence/relapse thereof.
- the present invention therefore also provides a drug selected from eslicarbazepine acetate and esUcarbazepine, for use in treating Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 and preventing the recurrence/relapse of Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 in a human patient.
- Bipolar Disorder 1 recurrence/relapse of Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 may be the same or different.
- the drug is particularly useful in the continuous treatment of patients who are susceptible to recurrence/relapse of Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1, as defined herein.
- the drug as defined above can be used as maintenance therapy to prevent the recurrence/relapse of episodes associated with Bipolar Disorder I, and/or to improve the patient's condition.
- the severity of Bipolar Disorder 1, in particular the manic and manic-type episodes associated therewith can be measured by reference to one or more standard indices.
- the Young Mania Rating Scale (YMRS) Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity.
- the British Journal of Psychiatry the journal of mental science. 1978;133 :429-35. Epub 1978/11/01.
- CGI-BP Clinical Global Impressions Scale for use in bipolar illness
- CGI Clinical Global Impressions
- BP bipolar illness
- Psychiatry Research. 1997;73(3): 159-71. Epub 1998/03/03. are widely used measures of mania and bipolar disorder which are sensitive to drug effects (Spearing et al, and Note for guidance on clinical investigation of medicinal products for the treatment and prevention of bipolar disorder, CPMP/EWP/567/98 (2001).).
- the YMRS score is the sum of 11 scoring items, ranging from 0 to 60 points; higher scores indicate higher mania symptomatology.
- the CGI-BP scale measures severity and treatment-related improvement in mania, depression and overall illness categories.
- the treatment of the present invention prevents recurrence/relapse of Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 as determined by the YMRS, CGI-BP and/or MADRS scales, preferably the YMRS and/or CGI-BP scales.
- the treatment of the present invention results in no worsening in the CGI-BP scale for the patient treated for as long as possible, for example for the particular period of time as defined above.
- the treatment of the present invention results in a YMRS score of less than 15 being maintained for as long as possible, for example for the particular period of time as defined above.
- Prevention of recurrence/relapse of Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 can be signified by a MADRS score of less than 18.
- prevention of recurrence/relapse of one or more depressive episodes is signified by a MADRS score of less than 18.
- the treatment of the present invention results in a MADRS score of less than 18 for as long as possible, for example for the particular period of time as defined above.
- the patient treated in accordance with the present invention is not suffering from Bipolar Disorder 1 or an episode associated with Bipolar Disorder 1 as defined herein.
- the patient treated in accordance with the present invention is not suffering from an episode associated with Bipolar Disorder 1 as defined herein, preferably a manic or mixed episode.
- the patient treated in accordance with the present invention is not suffering from Bipolar Disorder 1 or an episode associated with Bipolar Disorder 1 as defined herein as determined by the YMRS, CGI-BP and/or MADRS scales.
- the patient treated in accordance with the present invention is Caucasian.
- the patient treated in accordance with the present invention is at least 18 years of age.
- the patient treated in accordance with the present invention may be at least 16 years of age. In some embodiments, the patient treated in accordance with the present invention is less than 18 years of age.
- the patient treated in accordance with the present invention is susceptible to Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1, or is susceptible to relapse or recurrence of one or more episodes associated with Bipolar Disorder 1.
- Patients susceptible to Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 will typically have been diagnosed as suffering from Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1, preferably according to the DSM-IV criteria.
- Patients susceptible to Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 may have a family history of Bipolar Disorder 1 and/or other mood, affective or behavioral disorders and/or may already have experienced a mood, affective or behavioural disorder other than Bipolar Disorder 1.
- Bipolar Disorder 1 Patients susceptible to relapse or recurrence of one or more episodes associated with Bipolar Disorder 1 may experience roughening.
- treatment in accordance with the present invention improves the mood of the patient.
- Mood in treated patients can be self-evaluated, for instance using a 100- point visual analogue scale using, e.g., DiaryPROTM software (Invivodata®, Inc.) implemented on a touch-screen device (PalmTM OS).
- Mood is typically assessed by reference to the reported highest and/or lowest mood states for a patient.
- treatment in accordance with the present invention improves the highest and/or lowest mood of the patient.
- treatment in accordance with the present invention improves the average mood of the patient.
- the drug is eslicarbazepine acetate. In some embodiments, the drug is eslicarbazepine.
- the drug may also be used for treating partial onset seizures, for example in patients with epilepsy who are also susceptible to or suffering from Bipolar Disorder 1 and/or (relapse or recurrence of) one or more episodes associated therewith. Therefore the patient may be suffering from partial onset seizures and/or epilepsy.
- the drugs for use in the present invention may be administered as monotherapy treatment for the indication or with other drug(s) as adjunct therapy for the indication, as described in more detail below.
- the drugs for use in the present invention may be administered simultaneously, separately or sequentially with the other drug(s), for example in fixed dose combination or in separate doses.
- the drugs for use in the present invention may be administered by any suitable route to provide a preventative therapeutic effect against Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1.
- they can be administered orally, for example as tablets, capsules, caplets, troches, lozenges, aqueous or oily
- the drugs may also be administered parenterally, whether subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques.
- the drugs may also be administered as suppositories.
- the drugs are for oral administration.
- the drugs are administered as a tablet or capsule.
- the drugs are administered as a suspension. This embodiment is explained further in WO-A-2011/031176, the content of which is incorporated herein by reference.
- the drugs are administered as a granule formulation. This embodiment is explained further in WO-A-2012/091593, the content of which is incorporated herein by reference.
- the drugs for use in the present invention may be administered once a day, or more than once a day, for example two, three or four times a day. Typically, the drugs are for once daily administration.
- the drugs may be administered using a titration regime, starting on a lower dosage and increasing the dosage over time to the therapeutic dosage.
- patients may start taking 400mg once daily (QD) and titrate up in 400mg steps until they are taking 800mg or 1200 mg QD according to clinical response, or may start taking 800mg once daily (QD) and titrate up in 800mg steps until they are taking 1600mg or 2400mg QD according to clinical response, or may start taking 600mg QD and titrate up in 600mg steps until they are taking 1200mg or 1800mg according to clinical response.
- Titration may take place over several days or several weeks. For example, patients showing no improvement of symptoms over two, three, four, five days or over a week on one dosage may increase that dosage.
- Dosages will vary depending on, e.g., the individual, the mode and frequency of administration, and the nature and severity of the condition to be treated. A clinician having ordinary skill in the art can readily determine and prescribe the effective amount required.
- Typical doses for a patient will range from 1 mg per kilogram to 50 mg per kilogram of body weight per day.
- a typical daily oral dose of the drugs is from 100 mg to 4800 mg per day, preferably from 200 mg to 2400 mg per day, more preferably from 300 to 1800 mg per day.
- Examples of daily oral doses of the drugs include 300mg per day, 400mg per day, 600mg per day, 700mg per day, 800mg per day, 900mg per day, lOOOmg per day, 1 lOOmg per day, 1200mg per day, 1300mg per day, 1400mg per day, 1500mg per day, 1600mg per day, 1700mg per day, 1800mg per day, 1900mg per day, 2000 mg per day, 2100 mg per day, 2200 mg per day, 2300 mg per day, 2400 mg per day, 2500 mg per day, 2600 mg per day, 2700 mg per day, 2800 mg per day, 2900 mg per day, and 3000 mg per day.
- Eslicarbazepine acetate and eslicarbazepine may be administered as a monotherapy, or in combination with one or more therapeutic agents for the prevention of
- the drug is administered as a monotherapy, or in combination with one or more therapeutic agents for the prevention of
- the drug is administered as a monotherapy, or in combination with one or more therapeutic agents for the prevention of recurrence/relapse of Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 which is other than quetiapine.
- the present invention provides a drag selected from eslicarbazepine acetate and eslicarbazepine, for use in preventing the recurrence/relapse of Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 in a human patient who is not receiving quetiapine administered at a dosage of 400mg per day and/or levocetirizine administered at 5mg per day.
- the present invention provides a drug selected from eslicarbazepine acetate and eslicarbazepine, for use in preventing the recurrence/relapse of Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 in a human patient who is not receiving quetiapine and/or levocetirizine.
- Suitable therapeutic agents for use in combination with eslicarbazepine acetate and eslicarbazepine include lithium, anticonvulsants such as sodium valproate, carbamazepine, and lamotrigine, and antipsychotics such as risperidone, olanzapine and aripiprazole.
- the present invention also provides a pharmaceutical composition for use in preventing the recurrence/relapse of Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 as defined herein, in a patient as defined herein, which pharmaceutical composition comprises a pharmaceutically acceptable carrier and, as active principle, a drug as defined herein.
- Eslicarbazepine acetate and eslicarbazepine are typically formulated for administration with a pharmaceutically acceptable carrier or diluent.
- solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g. starches, arabic gums, gelatin, methylcellulose, povidone, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g.
- Such pharmaceutical preparations may be manufactured in any known manner, for example, by means of mixing, granulating, tableting, sugar coating, or film coating processes.
- Liquid dispersions for oral administration may be syrups, emulsions and suspensions.
- the syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
- Suspensions and emulsions may contain as carrier, for example a natural gum, xanthan gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
- the suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, a wetting agent, for example polyoxyethylene stearate, an antimicrobial agent, such as methylparaben or propylparaben, and if desired, a suitable amount of lidocaine hydrochloride.
- a pharmaceutically acceptable carrier e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol
- a wetting agent for example polyoxyethylene stearate
- an antimicrobial agent such as methylparab
- Solutions for injection or infusion may contain as a carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.
- the pharmaceutical composition is in the form of a tablet, granule formulation (i.e. for sprinkling on or adding to food or beverage) or suspension.
- Suitable tablets are described in WO- A- 2009/054743.
- Suitable granule formulations are described in WO-A- 2012/091593.
- Suitable suspensions are described in WO-A- 2011/031176.
- the present invention also provides use of a drug as defined herein, or a
- the present invention also provides a method of preventing the recurrence/relapse of Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 as defined herein, in a patient as defined herein, which method comprises admirdstering to said patient a safe and effective amount of a drug as defined herein, or a pharmaceutical composition as defined herein.
- the present invention also provides a method of preventing the recurrence/relapse of Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 as defined herein, which method comprises:
- the study schedule consisted of a screening visit (VI), randomisation visit (V2, Day 1), and subsequent visits to evaluate clinical response (V3, Day 4; V4, Day 7; V5, Day 10; V6, Day 14 and V7, Day 21).
- VI screening visit
- V2, Day 1 randomisation visit
- V3, Day 4 V4, Day 7; V5, Day 10; V6, Day 14 and V7, Day 21.
- the dose of study medication was increased every 3 days until the maximum doses were reached. If maximum doses showed no effect for 3 days, the patient was tapered off and switched to an open-label escape therapy with an established antimanic drug.
- patients who responded to treatment had the option of entering the recurrence prevention study (Study BIA-2093-205).
- Study BIA-2093-204 (EudraCT N° 2005-002133-13) followed a multicentre, double-blind, randomised, parallel-group, placebo-controlled, fixed multiple dose design. This study was conducted at 25 study centres in Europe, South Africa and South America. Patients were randomised (1 : 1 : 1 : 1) to one of the following treatment groups: (1) ESL 1800mg QD, (2) ESL 1200mg QD, (3) ESL 600mg QD, and (4) Placebo QD. The visit schedule in study BIA-2093-204 was similar to that of study BIA-2093-203. Patients who showed no improvement of symptoms by Day 10 were switched to open-label escape therapy with an established antimanic drug. Patients also had the option of entering Study BIA-2093-205.
- Study BIA-2093-205 (EudraCT N° 2005-002134-35) was a recurrence prevention study designed as a continuation of studies BIA-2093-203 and BIA-2093-204, and comprised two sequential parts. Part I followed an open-label design in which all participants received treatment with ESL 900mg QD for 2 weeks. Part II followed a double-blind, parallel-group, fixed multiple dose design in which participants were randomly assigned (1:1:1) to one of the following treatment groups: (1) ESL 1800mg QD, (2) ESL 900mg QD, and (3) ESL 300mg QD.
- BIA-2093-203 and BIA-2093-204 enrolled patients with ages >18 years, currently displaying an acute manic (including mixed) episode and with a documented diagnosis of bipolar I disorder according to the DSM-IV criteria (2). Eligible patients should have a Young Mania Rating Scale (YMRS) total score >20, with symptoms of the current manic episode starting within two weeks prior to randomization. Patients were excluded if they had history of schizophrenia or schizoaffective disorder, psychotic features or rapid cycling. Patients were also excluded if they were treated with carbamazepine, oxcarbazepine or a depot-neuroleptic.
- YMRS Young Mania Rating Scale
- the recurrence prevention study (BIA-2093-205) enrolled patients that completed the acute phase studies (BIA-2093-203 and BIA-2093-204) and responded to the treatment. Patients were excluded from Study BIA-2093-205 if any clinical relevant disorder arose at the time of inclusion.
- Prohibited bipolar disorder preventive medication included antidepressants, antipsychotics, antiparkinsonians, anxiolytics, monoamine oxidase inhibitors and other centrally acting drugs. Patients taking these medications had to be washed out for at least 2 days prior to
- YMRS (20), the Clinical Global Impressions - Bipolar Version (CGI-BP) scale (21) and the Montgomery-Asberg Depression Rating Scale (MADRS) (22).
- CGI-BP Clinical Global Impressions - Bipolar Version
- MADRS Montgomery-Asberg Depression Rating Scale
- the CGI-BP scale measures severity and treatment-related improvement in mania, depression and overall illness categories. It comprises 3 scales: severity of illness (1 - normal to 7 - very severely ill, in which 3 - mildly ill was used as cut-off value for statistical analysis), change from preceding phase and worst phase (1 - very much improved to 7 - very much worse, and 8 - not applicable) (21).
- the MADRS score is calculated as the sum of the 10 scoring items, ranging from 0 to 60 points: higher scores indicate higher depression symptomatology (22).
- the YMRS and the CGI-BP are widely used measures of mania and bipolar disorder and they are sensitive to drug effects (21, 23).
- the MADRS is a widely accepted measure of depression designed to be sensitive to change (23).
- the primary efficacy endpoint for acute mania studies was the change in YMRS total score from baseline until the end of the 3- week treatment period.
- Secondary efficacy variables based on the YMRS score included responder rate (proportion of patients with >50% improvement or ⁇ 12 points in the YMRS score), change in YMRS total score for each visit, proportion of patients in full remission (YMRS score ⁇ 12), and time to full remission.
- the primary efficacy endpoint was the proportion of patients who showed no worsening in the CGI-BP scale over Part II of the study. If the patient had— in change from preceding phase scale— a score of 5, 6, or 7 in any of 3 categories (mania, depression, or overall bipolar disorder), the illness was considered to have worsened.
- AEs were documented by the investigator with reference to intensity, dates of occurrence and resolution, outcome and relation to the treatment (causality). Furthermore, each AE was classified as being serious or non-serious. All patients with AEs were followed until their resolution. AEs were coded according to the Medical Dictionary for Regulatory Activities (MedDRA).
- MedDRA Medical Dictionary for Regulatory Activities
- the safety population consisted of all patients who received at least one dose of investigational product.
- the ITT population consisted of all randomised patients who had at least one post-baseline efficacy assessment.
- the PP population consisted of all patients who complied with the study protocol without major deviations.
- Demographic data and other baseline characteristics were summarised by treatment group using descriptive statistics.
- ANCOVA covariance
- Patient disposition is displayed in figure 1 and demographic characteristics are shown table 1.
- Study BIA-2093-203 was completed as planned: 161 patients received at least one dose of study medication and constituted the safety population. Similar percentages of patients in each treatment group discontinued from the study prematurely. The most common reason for discontinuation was withdrawal of consent. All patients in study BIA-2093-203 were Caucasian.
- Table 2 displays the YMRS absolute change from baseline results.
- YMRS total scores decreased from baseline to the end of the 3 -week treatment period for all treatment groups. This decrease was not dose related. Due to the reduced number of patients, the ANCOVA and the PP analysis were not performed.
- Proportion of patients who developed manic/depressive symptomatology For the ITT population, the proportion of patients with YMRS scores >15 (manic
- the mean (SD) overall lowest mood scores for the ESL 300mg, 900mg, and 1800mg groups during the double-blind period in the ITT population were respectively 45.9 (10.4), 47.3 (12.4), and 51.1 (12.3). Results were similar for the PP population.
- Table 3 presents the incidence of AEs occurring per treatment group. AEs occurred more frequently in the ESL groups than in the placebo group. The overall frequency of AEs was similar in the ESL 600- 1800mg and ESL 800-2400mg of study BIA-2093-203 groups whereas the ESL 1200mg and ESL 1800mg groups in study BIA-2093-204 had a higher frequency of AEs but with a limited number of patients. For all treatment groups, the most frequent types of AEs were nervous system and gastrointestinal disorders; these AEs also occurred more frequently in the ESL groups than in the placebo group.
- Treatment groups from studies BIA-2093-203 and BIA-2093-205 were well matched with respect to demographic characteristics and medical conditions at baseline. The use of prior and concomitant medications was similar between the treatment groups for all studies. Also the patient compliance rates were very high and homogeneous, registering a minimum value of 95%.
- the absolute differences observed between the ESL treatment groups and placebo for the YMRS total score were smaller than those used for sample size calculation (4.0 for ESL 800mg and 2.2 for ESL 600mg versus 6.4 in the sample size calculation).
- a significantly higher proportion of patients were in full remission at V7 in the ESL 800-2400mg group when compared to the placebo group.
- Responders in study BIA-2093-204 reflect the low number of patients, but also the uncharacteristic population subset, with response rates ranging from 56% to 100%— with a placebo response rate of 90.9%.
- Psychiatric disorders were the most frequent AEs.
- the safety results are in line with previous clinical studies with ESL in epileptic patients that reported dizziness, somnolence, headache, nausea, diplopia and vertigo as the most common AEs.
- AEs leading to discontinuation included dizziness, abnormal
- Body weight in kg mean ⁇ SD 81.8 ⁇ 16.7 78.3 ⁇ 17.6 76.0 ⁇ 14.6
- Body weight in kg mean ⁇ SD 81.8 ⁇ 16.7 76.5 ⁇ 17.1 71.7 ⁇ 13.3 74.9 ⁇ 18.1
- Body weight in kg mean ⁇ SD 78.4 ⁇ 20.4 b 73.8 ⁇ 12.5 81.8 ⁇ 12.8
- ESL Eslicarbazepine acetate
- N total number of patients
- n number of patients
- BMI body mass index
- SD standard deviation.
- Diarrhoea 0 (0.0) 8 (11.1) 2 (3.5) 0 (0.0) 0 (0.0)
- ESL Eslicarbazepine acetate
- n number of patients.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2015147233A RU2015147233A (en) | 2013-04-04 | 2014-04-04 | METHODS OF TREATMENT INCLUDING ESLICARBAZEPINE OR ESLICARBAZEPINE ACETATE |
JP2016506284A JP2016515616A (en) | 2013-04-04 | 2014-04-04 | Treatment with eslicarbazepine or eslicarbazepine acetate |
EP14718471.7A EP2981265A1 (en) | 2013-04-04 | 2014-04-04 | Treatments involving eslicarbazepine or eslicarbazepine acetate |
US14/780,922 US20160051560A1 (en) | 2013-04-04 | 2014-04-04 | Treatments involving eslicarbazepine or eslicarbazepine acetate |
CA2908706A CA2908706A1 (en) | 2013-04-04 | 2014-04-04 | Treatments involving eslicarbazepine or eslicarbazepine acetate |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1306095.9A GB201306095D0 (en) | 2013-04-04 | 2013-04-04 | New treatments |
GB1306095.9 | 2013-04-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014163518A1 true WO2014163518A1 (en) | 2014-10-09 |
Family
ID=48483325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/PT2014/000021 WO2014163518A1 (en) | 2013-04-04 | 2014-04-04 | Treatments involving eslicarbazepine or eslicarbazepine acetate |
Country Status (7)
Country | Link |
---|---|
US (1) | US20160051560A1 (en) |
EP (1) | EP2981265A1 (en) |
JP (1) | JP2016515616A (en) |
CA (1) | CA2908706A1 (en) |
GB (1) | GB201306095D0 (en) |
RU (1) | RU2015147233A (en) |
WO (1) | WO2014163518A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006121363A1 (en) * | 2005-05-06 | 2006-11-16 | Portela & C.A., S.A. | Eslicarbazepine acetate and methods of use |
WO2006120501A1 (en) * | 2005-05-06 | 2006-11-16 | Portela & C.A., S.A. | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
WO2011031176A1 (en) * | 2009-09-10 | 2011-03-17 | Bial - Portela & C.A., S.A. | Oral suspension formulations of esclicarbazepine acetate |
WO2012091593A1 (en) * | 2010-12-31 | 2012-07-05 | Bial - Portela & Ca., S.A. | Granulates comprising eslicarbazepine acetate |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9750747B2 (en) * | 2011-08-26 | 2017-09-05 | Bail-Portela & Ca, S.A. | Treatments involving eslicarbazepine acetate or eslicarbazepine |
-
2013
- 2013-04-04 GB GBGB1306095.9A patent/GB201306095D0/en not_active Ceased
-
2014
- 2014-04-04 WO PCT/PT2014/000021 patent/WO2014163518A1/en active Application Filing
- 2014-04-04 EP EP14718471.7A patent/EP2981265A1/en not_active Withdrawn
- 2014-04-04 US US14/780,922 patent/US20160051560A1/en not_active Abandoned
- 2014-04-04 CA CA2908706A patent/CA2908706A1/en not_active Abandoned
- 2014-04-04 RU RU2015147233A patent/RU2015147233A/en not_active Application Discontinuation
- 2014-04-04 JP JP2016506284A patent/JP2016515616A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006121363A1 (en) * | 2005-05-06 | 2006-11-16 | Portela & C.A., S.A. | Eslicarbazepine acetate and methods of use |
WO2006120501A1 (en) * | 2005-05-06 | 2006-11-16 | Portela & C.A., S.A. | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
WO2011031176A1 (en) * | 2009-09-10 | 2011-03-17 | Bial - Portela & C.A., S.A. | Oral suspension formulations of esclicarbazepine acetate |
WO2012091593A1 (en) * | 2010-12-31 | 2012-07-05 | Bial - Portela & Ca., S.A. | Granulates comprising eslicarbazepine acetate |
Non-Patent Citations (4)
Title |
---|
ALMEIDA ET AL: "Eslicarbazepine Acetate (BIA 2-093)", 20061230, vol. 4, no. 1, 30 December 2006 (2006-12-30), pages 88 - 96, XP005735281 * |
ALMEIDA L ET AL: "Efficacy and safety of eslicarbazepine acetate in acute manic episodes associated with bipolar I disorder: BIA-2093-203 phase II study results", JOURNAL OF NEUROLOGICAL SCIENCES, vol. 333, 15 October 2013 (2013-10-15), XP028722610, ISSN: 0022-510X, DOI: 10.1016/J.JNS.2013.07.152 * |
NATH KAMAL ET AL: "Eslicarbazepine acetate in the management of refractory bipolar disorder", CLINICAL NEUROPHARMACOLOGY, RAVEN PRESS, NEW YORK, NY, US, vol. 35, no. 6, 1 November 2012 (2012-11-01), pages 295, XP008170071, ISSN: 0362-5664, DOI: 10.1097/WNF.0B013E318271220B * |
See also references of EP2981265A1 * |
Also Published As
Publication number | Publication date |
---|---|
GB201306095D0 (en) | 2013-05-22 |
RU2015147233A3 (en) | 2018-03-21 |
CA2908706A1 (en) | 2014-10-09 |
RU2015147233A (en) | 2017-05-15 |
US20160051560A1 (en) | 2016-02-25 |
JP2016515616A (en) | 2016-05-30 |
EP2981265A1 (en) | 2016-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lamy et al. | Pharmacological management of behavioral disturbances in children and adolescents with autism spectrum disorders | |
Lyseng-Williamson | Levetiracetam: a review of its use in epilepsy | |
Trinka et al. | Pharmacotherapy for status epilepticus | |
Goldsmith et al. | Lamotrigine: a review of its use in bipolar disorder | |
Sanchez et al. | Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data | |
Hovinga | Levetiracetam: a novel antiepileptic drug | |
Wilens et al. | Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study | |
Vinik et al. | Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies | |
Weisler et al. | Extended-release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two randomised, double-blind, placebo-controlled trials | |
Weihs et al. | Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression | |
Reinares et al. | A systematic review on the role of anticonvulsants in the treatment of acute bipolar depression | |
McElroy et al. | Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial. | |
Sinzig et al. | Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder | |
Olin et al. | Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: A 26‐week, open‐label, prospective trial (Study ENA713B US32) | |
US20070185080A1 (en) | Pharmaceutical Compositions | |
Marino et al. | Paliperidone extended‐release for the treatment of schizophrenia | |
Akiskal et al. | Bipolar psychopharmacotherapy: caring for the patient | |
Meulien et al. | Safety and tolerability of once‐daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double‐blind, placebo‐controlled studies | |
Raskin et al. | Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder | |
Pollack et al. | Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies | |
Shiovitz et al. | A randomized, double-blind, placebo-controlled trial of the efficacy and safety of levomilnacipran ER 40-120mg/day for prevention of relapse in patients with major depressive disorder | |
Chrysant et al. | Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis | |
Nutt et al. | Early onset anxiolytic efficacy after a single dose of pregabalin: double-blind, placebo-and active-comparator controlled evaluation using a dental anxiety model | |
CA2913755A1 (en) | Methods of treatment and compositions with xanthine oxidase inhibitors | |
US20130217615A1 (en) | Combination treatment of major depressive disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14718471 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14780922 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2016506284 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2908706 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014718471 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201510725 Country of ref document: UA |
|
WWE | Wipo information: entry into national phase |
Ref document number: A20150533 Country of ref document: BY |
|
ENP | Entry into the national phase |
Ref document number: 2015147233 Country of ref document: RU Kind code of ref document: A |